Literature DB >> 8921053

Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.

R Fleming1, C C Chung, R W Yates, J R Coutts.   

Abstract

The effects of treatment of patients with gonadotrophin-releasing hormone analogue (GnRHa) combined with purified follicle stimulating hormone (FSH) for in-vitro fertilization (IVF) were investigated in detail to determine the influences of different administration routes and the degree of suppression of luteinizing hormone (LH). Responses to exogenous gonadotrophins were studied in infertile women (n = 60) with normal menstrual rhythm whose endogenous gonadotrophin activity was suppressed using a GnRHa in a long protocol. They were randomized to receive i.m. administration of human menopausal gonadotrophins (HMGim, Pergonal) or purified follicle stimulating hormone (FSH, Metrodin High Purity) administered either i.m. (MHPim) or s.c. (MHPsc). Responses were assessed by measuring plasma FSH, LH, oestradiol, testosterone and progesterone. After stimulation day 4, the MHPsc group showed significantly higher circulating concentrations of FSH than either the MHPim or HMGim group. However, the HMG group showed significantly higher oestradiol concentrations after stimulation day 5 than either MHP group. The differences in circulating oestradiol concentrations in the MHP-treated patients appeared to be strongly influenced by the mean circulating concentrations of LH in the follicular phase. The patients who showed mean follicular phase LH concentrations of < 1 IU/l showed longer follicular phases, lower circulating oestradiol and testosterone concentrations and also lower follicular fluid concentrations of oestradiol and testosterone, indicating a reduction in the normal follicular metabolism of progesterone to androgens and oestrogens under these conditions. This group of patients also showed longer follicular phases, which may have consequences for future clinical management.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921053     DOI: 10.1093/oxfordjournals.humrep.a019506

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

1.  A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

Authors:  S Bassil; C Wyns; J Donnez
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

2.  The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.

Authors:  J Balasch; M Creus; F Fábregues; S Civico; F Carmona; B Puerto; R Casamitjana; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2001-05       Impact factor: 3.412

3.  Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.

Authors:  Kyono Koichi; Nakajo Yukiko; Kumagai Shima; Sasaki Sachiko
Journal:  J Assist Reprod Genet       Date:  2006-06-20       Impact factor: 3.412

4.  Intracytoplasmic sperm injection after follicle stimulation with highly purified human follicle-stimulating hormone compared with human menopausal gonadotropin.

Authors:  A Weissman; J Meriano; S Ward; L Gotlieb; R F Casper
Journal:  J Assist Reprod Genet       Date:  1999-02       Impact factor: 3.412

5.  Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.

Authors:  Su-Long Lee; Jinu-Hwang Su; Katsuo Ikuta; Kaoru Suzumori
Journal:  Reprod Med Biol       Date:  2003-03-25

6.  Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin.

Authors:  Andrea F D Di Stefano; Antonio Rusca; Milko M Radicioni; Luca Loprete; Daniela Binelli; Giorgio Caccia; Barbara Cometti
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

7.  Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT.

Authors:  Ensieh Shahrokh Tehraninejad; Mina Farshbaf Taghinejad; Batool Hossein Rashidi; Fedyeh Haghollahi
Journal:  Int J Reprod Biomed       Date:  2017-07

8.  Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.

Authors:  José G Franco; Ricardo L R Baruffi; João Batista A Oliveira; Ana L Mauri; Claudia G Petersen; Paula Contart; Valeria Felipe
Journal:  Reprod Biol Endocrinol       Date:  2009-06-04       Impact factor: 5.211

9.  A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF).

Authors:  Carlo Alviggi; Alberto Revelli; Paola Anserini; Antonio Ranieri; Luigi Fedele; Ida Strina; Marco Massobrio; Nicola Ragni; Giuseppe De Placido
Journal:  Reprod Biol Endocrinol       Date:  2007-12-04       Impact factor: 5.211

10.  Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer.

Authors:  Abdelhamid Benmachiche; Sebti Benbouhedja; Abdelali Zoghmar; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-18       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.